Cross border exchange is an important way of increasing the number of organs available to a wider population, and is life-saving for specific patient groups such as urgent or highly-immunised patients and pediatric patients. Exchanging organs across borders is especially valuable for smaller countries because of their inherently limited donor and recipient pool.
ABEO Abeona Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. In addition, Abeona is developing a proprietary vector platform, AIM, for next generation product candidates. The company also has a T-cell program partnered with GSK, which has already shown preliminary evidence of tumor reduction in patients with synovial sarcoma and multiple myeloma.
ADVM Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin deficiency and Hereditary Angioedema as well as wet age-related macular degeneration.
Leveraging a next-generation adeno-associated virus AAV -based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop and commercialize gene therapy products for ophthalmic diseases, and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases.
In April of the U. AGTC AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases.
In addition to its product pipeline, AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.
Preclinical animal studies demonstrate high efficacy in primary tumors and an abscopal effect in remote tumors. This cure has been preliminarily confirmed during pilot runs of HIV patient blood.
AGT has also developed a synthetic gene that is capable of expressing therapeutic levels of human phenylalanine hydroxylase PAH to cure Phenylketonuria PKU that is expected to reach the clinic in ATRA Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases.
Atara is also developing off-the-shelf, allogeneic ATA and autologous ATA T-cell immunotherapies using a complementary targeted antigen recognition technology for specific EBV antigens believed to be important for the potential treatment of multiple sclerosis MS. ATHX Athersys is an international biotechnology company engaged in the development of therapeutic products designed to extend and enhance the quality of human life.
The company is especially focused on disease indications in the neurological, cardiovascular and inflammatory and immune disease areas, and other critical care indications. Food and Drug Administration. Their partner, Healios KK, is also conducting a parallel registrational trial in Japan.
BTX BioTime is a clinical-stage biotechnology company focused on degenerative diseases. Its clinical programs are based on two platform technologies: With its cell replacement platform, BioTime is producing new cells and tissues with its proprietary pluripotent cell technologies.
These cells and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative diseases or injuries. BLUE With its lentiviral-based gene therapies, T-cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer.
Founded in through one of the largest Series A financings in biotech history, BlueRock and its team of preeminent scientists are pioneering cell therapies that replace dead, damaged or dysfunctional cells to restore critical natural functions in the body.
BlueRock is initially targeting severe brain and heart conditions with the goal of altering the course of disease and drastically improving quality of life.
The B-MoGen team is equipped with proprietary tools and knowledge that have been developed into finely honed methods for efficient cellular engineering.
The company utilizes this unique expertise to provide three distinct services that address highly complex gene delivery and gene editing.
They offer a non-viral transposon-based gene delivery platform to support the T-cell immunotherapy industry; they are the first company in the world to demonstrate genome engineering of the mitochondria genome; and they offer fee-for-service custom cell engineering of both cell lines and, uniquely, primary human lymphohematopoietic cells for cancer research, drug screening and antibody validation.
CLBS Caladrius Biosciences is a clinical-stage development company with cell therapy products in development based on multiple technology platforms and targeting cardiovascular and autoimmune indications. Its late stage cardiovascular cell therapy targeting refractory angina recently received Regenerative Medicine Advanced Therapy RMAT designation and its critical limb ischemia program received Sakigake status in Japan.
Capricor is also exploring the potential of CAP, a cell-free, extracellular vesicle-based candidate, to treat a variety of disorders. We have two products in development. Our lead product, romyelocel-L, is a universal cell therapy to prevent infections during prolonged neutropenia.
Our second product, CLT is an antibody-drug conjugate in preclinical development to treat AML by targeting and killing leukemic stem cells, which are believed to be the cause of relapse in patients. CLT is directed at the C-type lectin-like molecule-1 CLL1which is highly expressed on leukemic stem cells, but not on normal hematopoietic stem or progenitor cells.Inventor Terry W.
Virts, Jr. NASA Astronaut & Dr.
Charles Terry Virts Astronaut Sends Vulcan Tribute to Leonard Nimoy From Final Frontier. Commercialization of organ transplantation: current legal and ethical state of affairs.
Commercialization of organ transplantation is arguably among the most complex and indefinite issues than human civilization currently faces, combining debates from ethical, legal, economic, and medical fields.
Commercialization of organ transplants Words | 8 Pages Commercialization of Organ Transplants I. Introduction: The following report contains a summary of the arguments for and against the commercialization of transplants found in the research.
Inflammatix is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. Con: Commercialization of Organ Transplants Thedebate on commercialization of human organs is a concept that has raised controversial issues, some of .
Messages saying, "Kidney for Sale, Urgent," are scrawled on walls outside hospitals in Tehran. Iran once had a thriving black market in kidney sales, but officials say illicit operations have ceased.